<DOC>
	<DOCNO>NCT01956838</DOCNO>
	<brief_summary>Rationale : The appearance tastants small intestine result activation negative feedback mechanism different part intestine stomach , small intestine central nervous system . These process inhibit food processing , appetite sensation food intake , furthermore increase feeling satiety satiation . We investigate effect intraduodenal infusion quinine 75mg ( bitter ) , rebaudioside A 540mg ( sweet ) , monosodium glutamate 2g ( umami ) , combination tastants ( quinine , rebaudioside A , monosodium glutamate ) placebo ( 5 test day total ) ad libitum food intake , satiation vivo release gut satiety peptide CCK GLP-1 . Study design : To assess effect intraduodenal infusion single ingredient combination tastants ( bitter , umami sweet ) ad libitum food intake . Secondary Objective ( ) : 1 . To investigate effect intraduodenal delivery combination tastants satiation . 2 . To assess effect intraduodenal delivery combination tastants gastrointestinal hormone release . 3 . To assess effect tastants quinine , rebaudioside A monosodium glutamate parameter mention primary objective , secondary objective 1 2 . 4 . To compare effect , mention primary objective , secondary objective 1 2 , combination tastants three single tastants quinine , rebaudioside A monosodium glutamate .</brief_summary>
	<brief_title>The Effect Bitter , Umami Sweet Tastants Food Intake</brief_title>
	<detailed_description />
	<criteria>Based medical history previous examination , gastrointestinal complaint define . Age 18 65 year . This study include healthy adult subject ( male female ) . Women must take contraceptive . BMI 18 25 kg/m2 ) Weight stable least last 6 month History severe cardiovascular , respiratory , urogenital , gastrointestinal/ hepatic , hematological/immunologic , HEENT ( head , ears , eye , nose , throat ) , dermatological/connective tissue , musculoskeletal , metabolic/nutritional , endocrine , neurological/psychiatric disease , allergy , major surgery and/or laboratory assessment might limit participation completion study protocol . The severity disease ( major interference execution experiment potential influence study outcome ) decide principal investigator . Use medication , include vitamin supplementation , except oral contraceptive , within 14 day prior test Administration investigational drug participation scientific intervention study may interfere study ( decided principle investigator ) , 180 day prior study Major abdominal surgery interfere gastrointestinal function ( uncomplicated appendectomy , cholecystectomy hysterectomy allow , surgery upon judgement principle investigator ) Dieting ( medically prescribe , vegetarian , diabetic , macrobiological , biological dynamic ) Pregnancy , lactation Excessive alcohol consumption ( &gt; 20 alcoholic consumption per week ) Smoking Blood donation within 3 month study period Selfadmitted HIVpositive state Weight &lt; 60kg Nontasters sweet , bitter umami Evidence MSGhypersensitivity Chinese restaurant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>food intake</keyword>
	<keyword>tastants</keyword>
	<keyword>obesity</keyword>
</DOC>